Meeting of the 139th Meeting of the IFCC Executive Board, November 20-22, 2019

Minutes

The 139th Meeting of the IFCC Executive Board was held in Jaipur, India at the Jaipur Conference Centre and the Jaipur Marriott Hotel.

Participants:

**EB Members**
- Maurizio Ferrari (MF) Past-President
- David Kinniburgh (DK) Secretary
- Tomris Ozben (TO) Treasurer
- Rolf Hinzmann (RH) Corporates Representative (Roche)

**IFCC Regional Federation Representatives**
- Adekunle Bashiru Okesina (ABO) African Federation of Clinical Chemistry (AFCC)
- Abderrazek Hedhili (AH) Arab Federation of Clinical Biology (AFCB)
- Sunil Sethi (SSE) Asia-Pacific Fed for Clinical Biochemistry and Lab Med (APFCB)
- Rosa Sierra-Amor (RSA) Latin-American Conf of Clin Biochemistry (COLABIOCLI)

**Invited Guests**
- Khosrow Adeli (KA) President Elect (2020-2021)
- Tahir Pillay (TP) Chair, CPD

**Absent**
- Sverre Sandberg (SSA) European Fed of Clin Chem and Lab Med (EFLM)

1.0 Preliminaries

1.0 Apologies for absence
SSA was not able to attend the meeting.

1.1.138 Minutes of 138th EB Meeting, Barcelona, Spain, May 19, 24 and 25, 2019.
The Full Minutes and the Summary Minutes from the 138th Meeting were approved for circulation to the EB and posting on the IFCC Website, with one correction to the Corporate Members Representative’s report.

Action List from 138th EB Meeting
The Action List from 138th EB Meeting was reviewed. Items were addressed or included elsewhere in the agenda. Those items yet to be addressed were added to the Action List from the current meeting.
Strategic Plan:
Review of the IFCC Executive Board Strategic Plan was deferred to the next EB meeting.

Area A: Supporting our Membership

<table>
<thead>
<tr>
<th>No.</th>
<th>Strategic Action</th>
<th>Responsible Party</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>a) Integration of educational programs</td>
<td>CPD</td>
</tr>
<tr>
<td></td>
<td>b) Continue to publicize educational resources available from IFCC</td>
<td>CPD</td>
</tr>
<tr>
<td></td>
<td>c) Work with National Members and Federations to make better use of the educational resources available from IFCC</td>
<td>EB, Reg Fed Reps, NS representatives</td>
</tr>
<tr>
<td></td>
<td>d) Continue to promote communication between National Members and Federations and coordinate activities. Explore use of Social Media to reach individuals directly.</td>
<td>EB, Reg Fed Reps, NS representatives</td>
</tr>
<tr>
<td></td>
<td>e) Continue to develop and present a series of webinars to meet the needs of Members.</td>
<td>CPD</td>
</tr>
<tr>
<td>2</td>
<td>a) Maintain and improve communication with COLABIOCLI and Members in Latin America, as required.</td>
<td>RSA / COLABIOCLI</td>
</tr>
<tr>
<td></td>
<td>b) Maintain and improve communication with AFCB and Members in Arab countries, as required.</td>
<td>AH / AFCB</td>
</tr>
<tr>
<td></td>
<td>c) Maintain and improve communication with AFCC and Members in African countries, as required.</td>
<td>AO / AFCC</td>
</tr>
<tr>
<td></td>
<td>d) Maintain and improve communication with EFLM and Members in the European countries, as required.</td>
<td>SSA / EFLM</td>
</tr>
<tr>
<td></td>
<td>e) Maintain and improve communication with APFCB and Members in the Asia-Pacific countries, as required.</td>
<td>SSE / APFCB</td>
</tr>
<tr>
<td></td>
<td>f) Maintain and improve communication with NAFCC and Members in the North American countries, as required.</td>
<td>AG / NAFCC</td>
</tr>
<tr>
<td>3</td>
<td>Conduct a survey of Young Scientists, sex, geography and corporate membership active in IFCC functional groups, and develop a plan to address any disparities.</td>
<td>DK/Office</td>
</tr>
<tr>
<td>4</td>
<td>Establish a Task Force, chaired and made up of Corporate Members, to identify and prioritize their needs, and possible projects, along with recommended membership. Assign to appropriate Division. Completed.</td>
<td>RH / Corp Mem reps within Divisions/ Divisional Exec Cttee’s EC.</td>
</tr>
<tr>
<td>5</td>
<td>Promote to Corporate Members the use of the IFCC Registry of Experts. Completed.</td>
<td>RH / Corp Mem reps within Divisions</td>
</tr>
</tbody>
</table>

Area B: Broadening Our Horizons

<table>
<thead>
<tr>
<th>No.</th>
<th>Strategic Action</th>
<th>Responsible Party</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>To translate the principles of metrology to one new project each year in areas of laboratory medicine other than clinical chemistry. Plan to participate in EMN – European Metrology Network meeting (June 2019)</td>
<td>P Gillery, SD</td>
</tr>
<tr>
<td>7</td>
<td>Establish at least one new collaboration each year with an international clinical organisation. An international scientific association, the European Society for Clinical Cell Analysis (ESCCA, President Anna Konstanti), is interested to join IFCC. PB to follow up on contact with ESCCA.</td>
<td>SD to identify projects and relevant clinical organizations and send EB their priorities. EB will then help to contact clinical organizations.</td>
</tr>
<tr>
<td>8</td>
<td>Invite organisations from outside laboratory medicine to contribute to the IFCC meetings to promote better interaction with healthcare professionals. Ask Divisions to organize symposia with clinical groups and make this a priority for COC and SPC. Establish a relationship with</td>
<td>EB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Div Chairs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AH</td>
</tr>
</tbody>
</table>
9. **Reach out to LIS vendors to collaborate on symposia presentations and development guidelines and standards of practice. Identify possible projects to standardize and harmonize post analytical LIS processes. Encourage IFCC Corporate membership from all informatics organizations.**

   SSE / Robert Flatman

10. **Explore the use of electronic meetings by IFCC functional groups. CPD to investigate suitable technologies. Zoom is one alternative. Paola to investigate this for a subscription and what the details are for cost and use and numbers. Then send out to all IFCC functional groups. Work with Silvia.**

   CPD, PB

11. **Explore the potential evolution of congress format to include electronic participation. MF to follow up with PCO. An alternative would be videotaping sessions that are then made available after the meeting. MF to investigate costs of on-line sessions. Live sessions would be challenging with different time zones. DK to follow up with IATDMCT to see what they are doing. AG to see what AACC is doing. Maybe these could be selective for key presentations.**

   JW, C-CC, MF, DK, AG

### Area C: Improving the Quality of Laboratory Medicine

<table>
<thead>
<tr>
<th>No.</th>
<th>Strategic Action</th>
<th>Responsible Parties</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>In conjunction with others develop resources to facilitate laboratory accreditation for developing countries. RSA says COLABIOCLI has just started a working group to address this. ABO says that Africa could follow along on this work.</td>
<td>EMD, DQCLM / ASLM</td>
</tr>
<tr>
<td>13a</td>
<td>Promote research demonstrating value of laboratory medicine. KA to join the VPLM on behalf of EB. EBLM could participate in this as well. Further discussion with the Divisions regarding this.</td>
<td>EMD (C-VPLM). DK/KA/Divs/CPD</td>
</tr>
<tr>
<td>13b</td>
<td>Leverage research in 13a to promote awareness of the IFCC and the value of lab medicine.</td>
<td>SSA</td>
</tr>
<tr>
<td>14</td>
<td>Strengthen the links and collaboration with the World Health Organization (WHO)</td>
<td>SSA</td>
</tr>
</tbody>
</table>

### Area D: Improving the Effectiveness of IFCC

<table>
<thead>
<tr>
<th>No.</th>
<th>Strategic Action</th>
<th>Responsible Parties</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Performance evaluation of functional units including EB including holding annual meetings with Division Chairs. Meetings to be organized for all Divisions for next year.</td>
<td>DK, SSA and RH</td>
</tr>
<tr>
<td>16</td>
<td>Develop a new fee structure and implementation plan for Affiliate members.</td>
<td>MF, TO, DK, PB</td>
</tr>
<tr>
<td>17</td>
<td>Review and revise Strategic Plan mid-year 2019. Defer until February of 2020 for new EB.</td>
<td>EB</td>
</tr>
</tbody>
</table>

### 2.0 Full Member Societies

#### 2.2 Applications for Full Membership

The "Laboratory Medicine Association of Georgia" was accepted as a Full Member. The application from "Myanmar Medical Technologists Association" is still pending.

#### 2.3 Annual Dues for Full Members

Syria, Algeria and Brazil have paid their dues. KA will pay the dues owed by the Iran Society for 2017-2018-2019. Iran Society will settle dues as of 2020A letter will be sent to the Belarus Society cancelling their membership for non-payment of dues. A letter will be sent to the Chinese Society advising them that their membership will be cancelled if payment of dues is not forthcoming. A letter will be sent to Sudan confirming that their...
dues will be paid on or before the Seoul Congress, or their membership will be cancelled. ABO has contacted Ethiopia and they hope to pay soon. SSE described the dues system for APFCB and will arrange for a copy to be sent to Paola for the EB.

3.0 Corporate Members
A report was provided by the Corporate Members Representative.

3.2 Applications for Corporate Membership
The applications for membership were approved for “Zhejiang Kuake Biotechnology Co. Ltd.” and “Agilent Technologies Inc” (via email). The application from “LLP Labtronic” was approved.

3.3 Removal of Corporate Members
A letter will be sent to “PPD” advising them of the termination of their membership for non-payment of dues.

3.4 Annual Dues for Corporate Members
The EB agreed that a late payment fee will be added to Corporate Members dues for 2020. A 5% fee will be added if not paid by end of March and a 10% fee will be added if not paid by end of June.

4.0 Affiliate Members

4.4 Annual Dues for Affiliate Memberships
Council has approved the EB request for delegation of authority for the EB to set the dues for the Affiliate members. The EB plan is to have Affiliate members pay a 50% discounted rate based on the number of members, but no higher than the Full member. Affiliate members will be asked to provide the number of members. Those who do not provide the information will be charged the same rate as the Full member. The change in fees will start for 2020. The IFCC Office to draft new plan for fees. TO and DK to review and submit to the EB for approval.

5.0 Regional Organisations
The EB approved 5 free registrations for the Federations to attend WorldLab Seoul. MF will send the request to the COC and President. The free registrations will be managed by each Federation. Criteria for awards include, YSs are strongly recommended, only one per country, evenly distributed, consideration of economic conditions of the country and economic need of applicant. Applicants will be sent to IFCC Office for distribution to the Federations.

5.1 Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB)
SSE provided a written report – See attached

5.2 Latin-American Confederation of Clinical Biochemistry (COLABIOCLI)
RSA provided a written report – See attached.

5.5 Arab Federation of Clinical Biology (AFCB)
AH provided a written report – See attached.
The EB discussed the Laboratory Medicine in Mobile Societies meeting and the lack of involvement of the IFCC as a full partner in the meeting. A discussion with EFLM is recommended to resolve the issue.

5.6 African Federation of Clinical Chemistry (AFCC)
ABO provided a written report – See attached.
ABO will provide more detail on the attendance, corporate sponsorship, and final profit.

6.0 International and Professional Organisations

6.13 World Association of Societies of Pathology and Laboratory Medicine (WASPaLM)
The EB agreed to change the agreement with WASPaLM to have 4 speakers instead of 3. PB will respond to WASPaLM.
7.0 Committee on Congresses and Conferences (C-CC)

7.1 Reviewed Guidelines for organizing IFCC-EFLM Congress were approved by EB via email.

7.2.24 IFCC WorldLab 2020, Seoul (KR), Seoul, May 24-28, 2020
SSE has replaced HM on the COC.

7.2.25 IFCC WorldLab 2023, Rome (IT), Rome, May 21-25, 2023
MF, KA and James Wesenberg will sit on the COC, IFCC will be Chair. Philippe will nominate 3 members of SD to sit on the SPC, EFLM will be Chair.

7.3 IFCC Regional Congresses of Clinical Chemistry and Laboratory Medicine

7.3.2.24 European Federation of Clinical Chemistry and Laboratory Medicine - EFLM
EuroMedLab 2019, Barcelona (ES)
Barcelona, May 19-23, 2019
The final budget statement should be available by the end of November.

7.3.6.15 Arab Federation of Clinical Biology – AFCB
Joint IFCC, EFLM and AFCB Tunisia 2020 meeting
Beirut 2021 meeting

7.9.13 IFCC General Conference:
The next GC should be in fall of 2021. This will be discussed with the President Elect at the first EB meeting of 2020.

7.40 Other Business
C-CC will be asked to bring greater attention to the IFCC policy on Predatory Conferences.

8.0 Scientific Division (SD) (pending possible SD Chair’s requests/uploads)

8.2 SD Committees
The EB approved SD EC second term appointments for P. Gilly, C. Cobbaert, K. Makris and Plebani.

8.2.6 An updated NPU Stakeholder SC Agreement was signed at the Copenhagen meeting. The renewal for Y.B.L. Hansen for a second term as a member was approved. The call for nominations for one new member was approved.

8.2.11 Molecular Diagnostics (C-MD)
The EB requested that the C-MD not replace the departing member at this time so as to keep the membership count consistent with other committees.

8.2.23 Traceability in Laboratory Medicine (C-TLM)
J Infusino, member - proposed as 2nd term 2020-2022. Approved by EB.

8.2.24 Reference Intervals and Decision Limits (C-RIDL)
Call for nominations for 2 members (J. Macri – B. Yadav 2nd finishing their term), in order to keep membership as it is. Approved by EB, with one to be a YS, if there is not already one on the committee.

8.2.25 Standardisation of Thyroid Function Tests (WG-STFT)
Call for nominations to replace 1 Member (J. Kratsch resigned). Approved by EB.

8.3.35 Standard of Hemoglobin A2 (WG-HbA2) – collaboration with ICSH new project. This request will be addressed via email or at the next EB meeting.

8.3.39 Standard of Albumin in Urine (WG-SAU)
Current Chair finished extra term, Jesse Seegmiller (US) proposed as Chair. Approved by EB.

8.3.41 Growth Hormone (WG-GH)
E. Lentjes, Chair – proposed 2nd term renewal. Approved by EB.

8.3.43 Standard of Troponin I (WG-TNI)
R. Christenson, Chair - proposed 2nd term renewal. The EB asks if the WG-TNI can merge with C-CM. DK to follow up with SD and EMD.

8.3.51 Commutability (WG-C)
Proposed creation of “WG on Commutability in Metrological Traceability - (WG-CMT)”. The EB will need more time to review this request, and will respond either by email or at the next EB.

8.3.54 Apolipoproteins by Mass Spectrometry (WG-APO MS)
8.3.55 Pancreatic Enzymes (WG PE)
D. Grote-Koska, Chair – proposed 2nd term renewal. Approved by EB.

8.3.56 Fecal Immunochemical Testing (WG-FIT)
S. Benton, Chair – proposed 2nd term renewal. Approved by EB.

8.13 Joint Committee for Traceability in Laboratory Medicine (JCTLM)
The EB approved the revised Declaration of Cooperation via email.
A report on the JCTLM was provided by Dr Myers.

8.15 SD Aspects of IFCC Specialized Conferences
8.16 International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR)
IFCC ICHCLR Symposium at WorldLab Seoul
The costs will be about $70,000 and the expected loss will be about $10,000. Attendance is expected to be 100-150 persons.
The 2018 Financial report was received (including payment of membership fee and charge for secretariat).

8.40. Other Business
The proposal for a Joint WG with ISTH to work on PT/INR standardization will be addressed via email or at the next EB meeting.

9.0 Education and Management Division (EMD)
9.2 EMD Committees
The EB approved the reestablishment of C-DL and C-leL via email.

9.2.4 Clinical Molecular Biology Curriculum (C-CMBC)
V. Haselmann proposed as Chair 1st term 2020-2022; E. Capoluongo 2nd term renewal 2020-2022. Approved by EB

9.2.5 Analytical Quality (C-AQ)
A. Thomas proposed as 2nd 2020-2022 term renewal as Chair and L. Khoroskaya as Member. Approved by EB.

9.2.7 Evidence Based Laboratory Medicine (C-EBLM)
N. Giménez Gomez 2nd term renewal 2020-2022. Approved by EB.

9.2.9 Clinical Laboratory Management (C-CLM)
P. Sharma proposed as Chair 1st term 2020-2022. Approved by EB.

9.2.10 Committee on Internet and Distance Learning (C-DL)
Update on the Pearls of Wisdom translation into Spanish (AG)
AG, RSA and DK have had meetings with Nadir and followed up with the AACC. Nadir has generously offered to cover the costs for this project. An MOU has been drafted and the sub-committee recommends the approval of this project. EB agreed. The EB expressed their gratitude for Nadir’s generosity.

9.2.11 Education in use of Biomarkers Diabetes (C-EUBD)

9.2.12 Committee on Cardiac Biomarkers
F. Apple proposed as Chair 2nd term 2020-2022 renewal as well as Members: P. Kavsak, A. Saenger, R. Body, SPC Lam as 2nd term renewal. Approved by EB.
The agreement with HHRI was approved by the EB via email.

9.2.13 Committee on Chronic Kidney Disease (C-KD)
New name is Committee for Kidney Diseases as approved by email.
Members P. Datta, M. Mussap, V. Radišić Biljak, proposed for 2nd term renewal 2020-2022. Approved by EB.
EMD-EC is monitoring the performance of this committee.

9.2.14 Committee on POCT
M. Vaubourdolle, M. Schwertfeger proposed 2nd term renewal 2020-2022. Approved by EB.

9.2.15 Committee on Proficiency Testing (C-PT)
A. Perret-Liaudet proposed as 1st term as Chair 2020-2022. Approved by EB.

9.2.16 Committee on Value Proposition for Laboratory Medicine (C-VPLM)

9.2.17 New UNIVANTS agreement with Abbott was signed, with EB approval via email.
9.3.8 Laboratory Errors and Patient Safety (WG - LEPS)  
M. Plebani proposed as Chair 1st term 2020-2022. Approved by EB.

9.3.10 Harmonisation interpretive comments (WG - ICQA)  
DK, MF, AG and KA met with Leslie and Sam. The WG has a new chair (Magdalena), a work plan, supporting personal and want to start this in Africa as a pilot that could be expanded to other regions. The project as the AFCC support. Approved by EB. DK will advise Leslie

9.4.1 VLP 2020 funding has been confirmed by Abbott for $50,000 USD.

9.4.3 Developing quality comp. in medical labs (DQCML)  
E. Amann was proposed for a 2nd term 2020-2022. Approved by EB.

9.30 Budget

9.40 Other Business:  
Reimbursement of publication costs in journals other than CCA. This item was put forward to the next EB meeting.  
A request should be sent to Siemens requesting funding for eNewsletter. PB to prepare letter, including a progress report.

10.0 Communications and Publications Division (CPD)

10.1 CPD Executive Committee  
Tahir Pillay joined the meeting to discuss CPD issues and concerns. Tahir is new to the position, as are a number of other CPD members, and a complete strategic plan is still being finalized. Katherina Psarra is the new eNews editor. Rajiv Erasmus is the new CPR Chair. A search is underway for a new IFCC Website editor. The CPD is working on adding at least 1 YS to all committees. The Internet and Learning committee has been split back into 2 committees but the 2 committees are not yet fully functional. The eJIFCC has had an increase in the number of submissions and is able to be more selective. It is time to renegotiate a new page allocation. The role of the WG –IFCC News was discussed and should be maintained to encourage and support input to the input to the e-News from member countries. Contributions to the eJIFCC or eNews can come from non-IFCC members, so long as the content is valuable to IFCC members. The CPR needs to update/revise and perhaps condense the PP presentation describing the IFCC. The consensus is that the IFCC Website does not need to be updated at this time, but Corporate Members and others have suggested that the IFCC make more use of Social Media. CPR has proposed that they should be responsible for IFCC Social Media activities and this needs to be determined by the EB to avoid confusion and overlap of activities. The e-Academy has not been as productive as hoped and EB asked that the EMD and CPD work together to determine a solution. A goal of 1 module per month was suggested. The CPD feels that El Microscopio is a good program but should report to the CPD, including review of expenses.

11.00 Emerging Technology Division (ETD)

11.1 Update on progress with the new Division  
DK will obtain more information on the video contest.  
The EB approved Helen Martin as a Consultant member of the EC.  
The EB asked for more information to support the request for increased funding for the ETD.

11.2.1 Committee for Emerging Technologies in Pediatric Laboratory Medicine (C-ETPLM)  
There are now 6 members but will reduce to 5 as first member’s term expires.

11.2.2 Committee on Mobile Health and Bioengineering in Laboratory Medicine (C-MHBLM)  
There are 5 members.

11.2.3 Committee for Omics Translations (C-OT)  
There is one corporate member position open.
12.0 IFCC Awards
12.1 Awards Committee
The deadline for nominations will be extended to the end of December if sufficient
nominations are not received. It was agreed that previous winners of an award will be at a
lower priority for a second award.
12.1.1 IFCC Distinguished Clinical Chemist Award (sponsor Yashraj Biotech Ltd.)
Funding has been received.
12.1.2 IFCC Henry Wishinsky Award for Distinguished International Service (Siemens)
Funding is expected to be received in 2020.
12.1.3 IFCC Award for Distinguished Contributions in Education (Abbott Diagnostics)
Funding has been received.
12.1.4 IFCC Abbott Award for Significant Contributions in Molecular Diagnostics
(Abbott Molecular)
Funding has been received.
12.1.5 Distinguished Award for Laboratory Medicine and Patient Care (Sekisui Diagnostics)
Funding has been received.
12.1.6 IFCC Robert Schaffer Award for Outstanding Achievements in the Development of
Standards for Use in Laboratory Medicine (NIST-CLSI)
Funding has been received.
12.1.8 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics (Hytest)
Funding is expected to be received in 2020.
12.1.9 Gérard Siest-Biologie Prospective Award (Stabiligen)
Funding has been received.
12.1.10 IFCC-Distinguished Women Scientist Award for Contributions to in vitro Diagnostics
(Yashraj Biotechnology Ltd-new 2020)
Funding has been received.

13.0 Special Projects and Task Forces
13.1.01 Task Force on Ethics (TF-Ethics)
The EB approved Dr. Joe Weincek as member of TF-E via email.
Joe has drafted a training module on Ethics. It is specific for volunteers now and will be
modified to make it applicable for IFCC members. The new officer/member on-boarding
letter will be modified to require individuals to confirm that they have taken Ethics module,
are aware of insurance requirements, and will comply.
13.1.06 Task Force for Young Scientists (TF-YS)
CCA (Anthony Newman) donated $1,000 to TF-YS
The EB approved a request to continue to fund the Lab Surfing project
13.2 Professional Exchange Programmes
AG prepared an advertisement for PEP applications. This was circulated on the AACC
Artery & IFCC eNews.
13.15 Task Force Corporate Members (TF-CM)
A number of items from the C-CM were discussed.
1. The proposal to develop a structure for better communication among Corporate
members was supported by the EB.
2. The EB will explore the possibility of some relationship with MedTech Europe relative
to our efforts to promote the value of Laboratory Medicine. This may be more
appropriate at the national level. AG and DK to contact the AACC and CSCC to see if
they are working with their national IVD organizations. Tracey Ellison (corresponding
member of TF-CM) has been appointed as a consultant to C-VPLM).
3. It was suggested that the IFCC could play a greater role influencing or responding to
proposed European (or other national) regulations regarding IVD products.
The EMD and SD will be asked to help identify what disease groups are the most
important ones to focus IFCC efforts on.
4. It was decided that the EFLM should take the lead in assisting laboratories to respond
to the new IVDR rules. IFCC will help if required.
5. The EB agreed that any entertainment at a congress will be billed to the delegate as a separated and optional line item on the registration form. The C-CC will get a ruling from MedTech on this approach.

6. The EB agreed to the proposal that the TF-CM work to enhance the visibility of Corporate Member contributions (social media).

7. The EB will contact the COC Chair for Munich and ask them to reverse the decision to raise the fees for Corporate sponsors. It was also suggested that the rules for WorldLab and EuroMedLab should be changed to require IFCC and EFLM (where required) approval for changes to fees and budget issues. The C-CM concerns and suggestions regarding EuroMedLab Munich Congress facilities will be forwarded to MZ for their information and response.

8. Five Division Committees will be identified where a Corporate member could be added.

15.0 Financial Matters
TO reviewed the current income and expense summary, and the IFCC Investments and no issues were identified. The performance of the Investments was noted to be very good, particularly in light of our decreased charges. No issues were identified by the Audit. The Auditor’s method of reviewing the IFCC financial records was discussed and it was felt to be consistent with generally accepted accounting practices. MF, TO, KA will meet in Milan on February 26 to better understand the Office procedures, including those related to finances.

16.0 Organisational Matters
16.3 Procedures Manual
The Procedures Manual is under review.
Nominations Committee:
MF has resigned from the Nominations Committee due to becoming IFCC President. Loralie Langman (USA) and Alexander Haliassos (Greece) have been nominated for Treasurer. Tahir Pillay (South Africa) and David Kinniburgh (Canada) have been nominated for Secretary.
The call for nominations for the Regional Representatives and Corporate Representative has gone out.

16.4 Annual Report
The Annual report for 2019 will be prepared as per usual deadlines.

16.40 Other business:
A statement will be added to the on-boarding letter that advises new offices that they must comply with the IFCC policy on conflict of interest, and they are responsible to purchase their own travel medical insurance, but are provided a fixed amount of funds for each expense claim to offset the cost.

18. IFCC Foundation for Emerging Nations (FEN)
A report was received from FEN. The FEN has received additional funding which is sufficient for activities to continue into 2020.

19.0 Meetings
19.6 General Conference: Planned for 2021
19.80 Executive Board Meetings 2019
The next EB meeting will be at Lake Maggiore, Belgirate, February 27-29, 2020. MF, KA, TO and DK will meet with Office staff, and MZ, in Milan, on February 26. The EB will meet in Seoul on May 28, 29 and 30, after the congress.
Meetings with Divisions’ Chairs:
The EB will meet with Philippe to review the SD operations during the February meeting. Additional meetings with Division Chairs will be held at the Seoul Congress.